A Study of LNP3794 in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 22, 2020

Primary Completion Date

February 23, 2022

Study Completion Date

June 30, 2022

Conditions

NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors

Interventions

DRUG

LNP3794

LNP3794 capsules administered orally once daily

Trial Locations (4)

Cliniques universitaires Saint-Luc, Brussels

Amsterdam UMC, Amsterdam

Sarah Cannon Research Institute, London

The Christie NHS Foundation, Manchester

All Listed Sponsors

lead

Lupin Ltd.

INDUSTRY

NCT05187858 - A Study of LNP3794 in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors | Biotech Hunter | Biotech Hunter